Atara Biotherapeutics (ATRA) Stock Forecast for 2023 – 2026. Sell or Buy?
Updated: December 5, 2023 (12:38)
Sector: HealthcareThe share price of Atara Biotherapeutics, Inc. (ATRA) now
50/200 Day Moving Average: $1.136 / $2.025
This figure corresponds to the Average Price over the previous 50/200 days. For Atara Biotherapeutics stocks, the 50-day moving average is the resistance level today.
For Atara Biotherapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Atara Biotherapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Atara Biotherapeutics stock price in 2024, 2025, 2026, 2027, 2028. How much will one Atara Biotherapeutics share be worth in 2024 - 2028?
When should I take profit in Atara Biotherapeutics stock? When should I record a loss on Atara Biotherapeutics stock? What are analysts' forecasts for Atara Biotherapeutics stock? What is the future of Atara Biotherapeutics stock? We forecast Atara Biotherapeutics stock performance using neural networks based on historical data on Atara Biotherapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Atara Biotherapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Atara Biotherapeutics shares. This happens once a day.
Historical and forecast chart of Atara Biotherapeutics stock
The chart below shows the historical price of Atara Biotherapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Atara Biotherapeutics stock price can be found in the table below.
Long-term forecasts by years.
Atara Biotherapeutic, Inc., a turnkey T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. He is developing tabelecleucel, a T-cell immunotherapy phase III clinical trial for the treatment of rituximab-refractory Epstein-Barr virus (EBV) associated with post-transplant lymphoproliferative disorder, as well as other EBV-related hematological and solid tumors, including carcinoma of the nasopharynx. The company is also developing next-generation CAR T immunotherapy for patients with hematologic malignancies and solid tumors, as well as viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 For B-cell lymphomas, and ATA188, which are in phase I clinical trials for the treatment of multiple sclerosis. He also develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms tumor 1; and ATA621 for BK and JCV. The company has a licensing agreement with the Sloan Kettering Memorial Cancer Center; a license agreement for cooperation in research and development with the Kimr Berghofer Medical Research Institute; and strategic cooperation with the H. Lee Moffitt Cancer Center. Atara Biotherapeutic, Inc. The company was founded in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec 07 | 0.72 | 0.72 | 0.74 | 3.33 |
| Dec 08 | 0.73 | 0.72 | 0.74 | 2.42 |
| Dec 09 | 0.71 | 0.71 | 0.72 | 2.02 |
| Dec 10 | 0.71 | 0.69 | 0.72 | 3.29 |
| Dec 11 | 0.73 | 0.72 | 0.74 | 2.77 |
| Dec 12 | 0.73 | 0.72 | 0.75 | 3.72 |
| Dec 13 | 0.73 | 0.71 | 0.74 | 4.10 |
| Dec 14 | 0.74 | 0.72 | 0.74 | 3.78 |
| Dec 15 | 0.75 | 0.74 | 0.75 | 2.43 |
| Dec 16 | 0.73 | 0.71 | 0.73 | 3.66 |
| Dec 17 | 0.72 | 0.71 | 0.73 | 2.71 |
| Dec 18 | 0.71 | 0.71 | 0.72 | 1.91 |
| Dec 19 | 0.73 | 0.72 | 0.74 | 2.78 |
| Dec 20 | 0.73 | 0.72 | 0.74 | 2.53 |
| Dec 21 | 0.74 | 0.73 | 0.75 | 2.48 |
| Dec 22 | 0.75 | 0.74 | 0.76 | 3.21 |
| Dec 23 | 0.75 | 0.74 | 0.75 | 2.04 |
| Dec 24 | 0.77 | 0.75 | 0.78 | 4.25 |
| Dec 25 | 0.75 | 0.75 | 0.76 | 1.85 |
| Dec 26 | 0.75 | 0.73 | 0.75 | 3.38 |
| Dec 27 | 0.75 | 0.74 | 0.76 | 3.49 |
| Dec 28 | 0.74 | 0.73 | 0.75 | 2.65 |
| Dec 29 | 0.74 | 0.73 | 0.75 | 2.58 |
| Dec 30 | 0.76 | 0.76 | 0.77 | 1.91 |
| Dec 31 | 0.75 | 0.74 | 0.76 | 2.79 |
| Jan 01 | 0.74 | 0.74 | 0.76 | 3.61 |
| Jan 02 | 0.73 | 0.72 | 0.74 | 2.63 |
| Jan 03 | 0.72 | 0.71 | 0.73 | 2.81 |
| Jan 04 | 0.73 | 0.72 | 0.75 | 4.10 |
| Jan 05 | 0.71 | 0.70 | 0.73 | 3.22 |
Atara Biotherapeutics Daily Price Targets
Atara Biotherapeutics Stock Forecast 12-07-2023.
Forecast target price for 12-07-2023: $0.72.
Positive dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 3.227%.
Pessimistic target level: 0.72
Optimistic target level: 0.74
Atara Biotherapeutics Stock Forecast 12-08-2023.
Forecast target price for 12-08-2023: $0.73.
Positive dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 2.363%.
Pessimistic target level: 0.72
Optimistic target level: 0.74
Atara Biotherapeutics Stock Forecast 12-09-2023.
Forecast target price for 12-09-2023: $0.71.
Negative dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 1.984%.
Pessimistic target level: 0.71
Optimistic target level: 0.72
Atara Biotherapeutics Stock Forecast 12-10-2023.
Forecast target price for 12-10-2023: $0.71.
Negative dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 3.183%.
Pessimistic target level: 0.69
Optimistic target level: 0.72
Atara Biotherapeutics Stock Forecast 12-11-2023.
Forecast target price for 12-11-2023: $0.73.
Positive dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 2.694%.
Pessimistic target level: 0.72
Optimistic target level: 0.74
Atara Biotherapeutics Stock Forecast 12-12-2023.
Forecast target price for 12-12-2023: $0.73.
Positive dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 3.587%.
Pessimistic target level: 0.72
Optimistic target level: 0.75
ATRA (ATRA) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan. | 0.69 | 0.67 | 0.75 | 10.70 |
| Feb. | 0.77 | 0.74 | 0.80 | 7.13 |
| Mar. | 0.76 | 0.74 | 0.81 | 8.24 |
| Apr. | 0.72 | 0.67 | 0.79 | 14.48 |
| May. | 0.64 | 0.60 | 0.69 | 12.59 |
| Jun. | 0.67 | 0.63 | 0.71 | 10.50 |
| Jul. | 0.73 | 0.67 | 0.79 | 15.22 |
| Aug. | 0.74 | 0.68 | 0.79 | 13.27 |
| Sep. | 0.76 | 0.71 | 0.83 | 14.49 |
| Oct. | 0.80 | 0.78 | 0.86 | 9.37 |
| Nov. | 0.76 | 0.73 | 0.80 | 7.86 |
| Dec. | 0.73 | 0.69 | 0.74 | 7.27 |
Atara Biotherapeutics forecast for this year
Atara Biotherapeutics Stock Prediction for Jan 2024
An downtrend is forecast for this month with an optimal target price of $0.69211. Pessimistic: $0.67. Optimistic: $0.75
Atara Biotherapeutics Stock Prediction for Feb 2024
An uptrend is forecast for this month with an optimal target price of $0.768518. Pessimistic: $0.74. Optimistic: $0.80
Atara Biotherapeutics Stock Prediction for Mar 2024
An downtrend is forecast for this month with an optimal target price of $0.761141. Pessimistic: $0.74. Optimistic: $0.81
Atara Biotherapeutics Stock Prediction for Apr 2024
An downtrend is forecast for this month with an optimal target price of $0.718212. Pessimistic: $0.67. Optimistic: $0.79
Atara Biotherapeutics Stock Prediction for May 2024
An downtrend is forecast for this month with an optimal target price of $0.644093. Pessimistic: $0.60. Optimistic: $0.69
Atara Biotherapeutics Stock Prediction for Jun 2024
An uptrend is forecast for this month with an optimal target price of $0.66728. Pessimistic: $0.63. Optimistic: $0.71
Atara Biotherapeutics Stock Prediction for Jul 2024
An uptrend is forecast for this month with an optimal target price of $0.734542. Pessimistic: $0.67. Optimistic: $0.79
Atara Biotherapeutics Stock Prediction for Aug 2024
An uptrend is forecast for this month with an optimal target price of $0.738068. Pessimistic: $0.68. Optimistic: $0.79
Atara Biotherapeutics Stock Prediction for Sep 2024
An uptrend is forecast for this month with an optimal target price of $0.761095. Pessimistic: $0.71. Optimistic: $0.83
Atara Biotherapeutics Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $0.804021. Pessimistic: $0.78. Optimistic: $0.86
Atara Biotherapeutics Stock Prediction for Nov 2024
An downtrend is forecast for this month with an optimal target price of $0.756745. Pessimistic: $0.73. Optimistic: $0.80
Atara Biotherapeutics Stock Prediction for Dec 2024
An downtrend is forecast for this month with an optimal target price of $0.726778. Pessimistic: $0.69. Optimistic: $0.74
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 0.74 | 0.70 | 0.80 | 13.13 |
| Feb | 0.79 | 0.72 | 0.83 | 13.53 |
| Mar | 0.77 | 0.74 | 0.84 | 12.15 |
| Apr | 0.81 | 0.74 | 0.84 | 12.09 |
| May | 0.82 | 0.75 | 0.89 | 15.65 |
| Jun | 0.90 | 0.84 | 0.93 | 9.93 |
| Jul | 0.97 | 0.91 | 1.01 | 9.78 |
| Aug | 0.90 | 0.86 | 0.98 | 11.78 |
| Sep | 0.92 | 0.86 | 0.97 | 11.81 |
| Oct | 0.96 | 0.89 | 1.04 | 15.15 |
| Nov | 0.90 | 0.83 | 0.97 | 14.93 |
| Dec | 0.93 | 0.89 | 1.00 | 11.32 |
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 0.89 | 0.83 | 0.95 | 12.92 |
| Feb | 0.95 | 0.87 | 0.98 | 11.37 |
| Mar | 1.04 | 0.95 | 1.14 | 16.88 |
| Apr | 1.06 | 1.00 | 1.13 | 11.63 |
| May | 1.02 | 0.97 | 1.07 | 8.91 |
| Jun | 0.92 | 0.85 | 0.96 | 11.21 |
| Jul | 0.88 | 0.83 | 0.96 | 13.95 |
| Aug | 0.98 | 0.95 | 1.08 | 11.85 |
| Sep | 0.94 | 0.88 | 1.02 | 13.46 |
| Oct | 1.05 | 0.98 | 1.12 | 12.54 |
| Nov | 1.05 | 0.96 | 1.09 | 12.38 |
| Dec | 1.08 | 1.04 | 1.12 | 7.03 |
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.14 | 1.10 | 1.18 | 6.71 |
| Feb | 1.28 | 1.19 | 1.36 | 12.54 |
| Mar | 1.23 | 1.12 | 1.29 | 13.71 |
| Apr | 1.11 | 1.01 | 1.19 | 15.06 |
| May | 1.15 | 1.05 | 1.26 | 16.46 |
| Jun | 1.14 | 1.04 | 1.24 | 16.07 |
| Jul | 1.08 | 0.99 | 1.18 | 16.62 |
| Aug | 1.19 | 1.13 | 1.28 | 11.53 |
| Sep | 1.33 | 1.24 | 1.40 | 11.50 |
| Oct | 1.37 | 1.31 | 1.50 | 12.28 |
| Nov | 1.38 | 1.30 | 1.42 | 8.16 |
| Dec | 1.48 | 1.42 | 1.59 | 10.61 |
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2028
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.52 | 1.44 | 1.58 | 8.98 |
| Feb | 1.67 | 1.56 | 1.73 | 9.52 |
| Mar | 1.79 | 1.66 | 1.93 | 13.83 |
| Apr | 1.86 | 1.79 | 1.90 | 5.74 |
| May | 1.95 | 1.81 | 2.13 | 15.07 |
| Jun | 1.84 | 1.69 | 2.00 | 15.69 |
| Jul | 1.65 | 1.53 | 1.76 | 13.24 |
| Aug | 1.69 | 1.62 | 1.76 | 7.72 |
| Sep | 1.62 | 1.52 | 1.67 | 8.74 |
| Oct | 1.64 | 1.57 | 1.77 | 11.01 |
| Nov | 1.68 | 1.59 | 1.80 | 11.66 |
| Dec | 1.64 | 1.60 | 1.73 | 7.40 |
Atara Biotherapeutics information and performance
611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US
Market capitalization of the Atara Biotherapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ATRA shares in the company outstanding by the market price of one share.
EBITDA of Atara Biotherapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
